Guosong Liu
Neurocentria, USA
Title: Effi cacy and safety of MMFS-01, a synapse density enhancer, for reversing age-related cognitive decline: A randomized, double-blind, placebo-controlled trial
Biography
Biography: Guosong Liu
Abstract
Background: Age-related cognitive decline is a major problem in elderly, aff ecting quality of life. Pre-clinical studies show that MMFS-01, a synapse density enhancer, is eff ective at reversing cognitive decline in aging rodents. Objective: Since brain atrophy during aging is strongly associated with both cognitive decline and sleep disorder, we evaluated the effi cacy of MMFS-01 in its ability to reverse cognitive decline and improve sleep. Methods: We conducted a randomized, double-blind, placebo-controlled, parallel designed trial in elderly subjects (age 50- 70) with complaints of memory impairment, sleep disorder, and anxiety. Subjects were treated with MMFS-01 (n=23) or placebo (n=21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains. Results: With MMFS-01 treatment, overall cognitive ability improved signifi cantly relative to placebo (p=0.002; Cohen’s d=0.92). Age-related cognitive fl uctuation was also reduced. Although the study population had more severe executive function defi cits than age-matched controls, MMFS-01 treatment nearly restored impaired executive function, demonstrating that MMFS-01 was clinically signifi cant. Sleep quality and anxiety were improved in MMFS-01 treatment group; however, similar degrees of improvement were also observed in the placebo control group. Conclusions: Th e current study demonstrates the potential of MMFS-01 for treating age-related cognitive decline in elderly.